Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533826 · ClinicalTrials.gov registry record · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Ana C Garrido-Castro, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
- 11
- Study locations
NCT06533826 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Ana C Garrido-Castro, MD. The registered enrollment target is 357 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT06533826, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Ana C Garrido-Castro, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)
Conditions Studied
Interventions
- DRUG Datopotamab Deruxtecan
- DRUG Trastuzumab Deruxtecan
Study Locations (11)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Alabama
- University of Alabama - Birmingham
California
- University of San Francisco - San Francisco
Connecticut
- Yale University Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2038-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06533826
The ClinicalTrials.gov registry entry for NCT06533826 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Ana C Garrido-Castro, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Datopotamab Deruxtecan is the first listed.
NCT06533826 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06533826 about?
NCT06533826 is a clinical study titled "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd". The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER...
What is the current status of trial NCT06533826?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2024-10-29. Estimated completion is 2038-08-01.
What conditions does trial NCT06533826 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, HER2-Negative Breast Cancer, HER2 Low Breast Cancer.
What interventions are being tested in trial NCT06533826?
The interventions under investigation include: Datopotamab Deruxtecan (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06533826?
This trial is sponsored by Ana C Garrido-Castro, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533826 being conducted?
This trial has 11 study locations across Alabama, California, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.